E-DRUG: Independent Drug and Healthcare Newsletter for November 2019
-----------------------------------------------------------------------------------------
Newsletter, November 2019
Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection
First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options?
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD In the November issue of Prescrire International - Gliptins: joint pain and exposure to NSAIDs
In the Adverse Effects section of the November issue, the results of a study by the independent French medical journal Prescrire, based on data from France's national health insurance system.
Read more
--------------------------------------------------------------------------------
SUBSCRIBE NOW Subscribe today for full access to top-quality content from Prescrire International
Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries).
Subscribe now
--------------------------------------------------------------------------------
Gemtuzumab ozogamicin (Mylotarg°) in acute myeloid leukaemia: no proven benefits
According to currently available clinical evaluation data, gemtuzumab ozogamicin (Mylotarg°) does not provide tangible benefits for patients with acute myeloid leukaemia.
Read more
--------------------------------------------------------------------------------
Fenspiride (Pneumorel°): serious adverse effects reported over two decades
Despite serious adverse effects reported for more than 20 years, fenspiride (Pneumorel°) was only withdrawn from the market in 2019.
Read more
--------------------------------------------------------------------------------
Industrial protectionism and medicines: too many damaging effects
Pharmaceutical companies benefit from strong industrial protection which allows them to charge exorbitant prices for their medicines for a very long time.
Read more
--------------------------------------------------------------------------------
ADVANCING HEALTHCARE POLICY The European Medicines Agency's independence is paramount: concrete alternatives to the fee-for-service system must be found (October 2019)
Prescrire's response to a public consultation from the European Commission on the revision of the EMA fee system emphasises that EMA needs to be weaned off a fee-for-service relationship with pharmaceutical companies and funded through public funding from the European Union. Prescrire also called on for adequate public funding for independent post-marketing studies.
Read more
--------------------------------------------------------------------------------
COMING SOON Enjoy these features, and more, in our upcoming issues
Emicizumab in haemophilia A
Colchicine and acute pericarditis
Lamotrigine: preventing severe cutaneous adverse reactions
NSAIDs: nephrotoxicity in young, healthy adults
New drugs: the key role of publicly-funded research in the United States...
Subscribe now
Share this with a friend or colleague: Forward this email
Prescrire International <international@prescrire.org>